West Pharmaceutical (WST) Reports Q4 Earnings: What Key Metrics Have to Say

Core Insights - West Pharmaceutical Services (WST) reported revenue of $805 million for the quarter ended December 2025, reflecting a year-over-year increase of 7.5% and surpassing the Zacks Consensus Estimate by 1.35% [1] - The company's EPS for the quarter was $2.04, up from $1.82 in the same quarter last year, resulting in an EPS surprise of 11.21% compared to the consensus estimate of $1.83 [1] Financial Performance Metrics - Organic revenue growth was reported at 3.3%, exceeding the average analyst estimate of 1.8% [4] - Net sales from contract-manufactured products reached $143.2 million, slightly below the average estimate of $144.45 million, but showing a year-over-year increase of 6.2% [4] - Net sales from proprietary products amounted to $661.8 million, surpassing the average estimate of $648.56 million and representing a 7.8% increase compared to the previous year [4] - Gross profit from proprietary products was $285.7 million, exceeding the average estimate of $257.16 million [4] - Gross profit from contract-manufactured products was reported at $18.2 million, which fell short of the average estimate of $25.76 million [4] Stock Performance - Over the past month, shares of West Pharmaceutical have declined by 10.5%, while the Zacks S&P 500 composite experienced a minor decline of 0.3% [3] - The stock currently holds a Zacks Rank 2 (Buy), indicating potential for outperformance in the near term [3]